Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
HUM · against 61 other Healthcare companies of similar size
Ranked #25 of 62 · scores higher than 59% of peers
Bars: peers in each 10-point band of the valuation score12 peers with a valuation score of 60–69, including HUM · Click a bar to see the companies
Mainly thanks to its EBITDA yield and free cash flow yield, which are stronger than most Healthcare peers.
| Metric | HUM | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 59 reported | 2.5% | 3.0% | 38% | 30% | |
| EBITDA yieldHigher is better · 63 reported | 8.7% | 6.2% | 85% | 50% | |
| Free cash flow yieldHigher is better · 46 reported | 3.9% | 4.0% | 49% | 20% | |
| Book yieldHigher is better · 58 reported | 38.3% | 22.2% | 68% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 4.61T JPY (≈$31.3B) | 93 | 76 | |
| 2 | 78.1B USD | 89 | 60 | |
| 3 | 97.5B USD | 87 | 67 | |
| 4 | 6.17T JPY (≈$42.0B) | 86 | 70 | |
| 5 | 45.9B USD | 84 | 61 | |
| 22 | 32.8B USD | 68 | 69 | |
| 23 | 64.8B EUR (≈$71.3B) | 67 | 51 | |
| 24 | 27.3B USD | 66 | 55 | |
| 25 | 225.2B CNY (≈$31.5B) | 64 | 63 | |
| 25 | 50.2B USD | 64 | 49 | |
| 27 | 28.7B USD | 63 | 52 | |
| 28 | 84.5B EUR (≈$92.9B) | 62 | 51 | |
| 29 | 36.8B USD | 61 | 46 | |
| 29 | 100.2B USD | 61 | 68 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score